BridgeMD
New treatment option for Hemiplegic Shoulder Pain
Official title Suprascapular Nerve Block and Proprioception in Hemiplegic Shoulder Pain: A Randomized Controlled Study
ClinicalTrials.gov ID: NCT07346755
What this study is testing
- What it's testing
- The purpose of this prospective randomized controlled clinical trial is to evaluate the effect of suprascapular nerve block on shoulder joint proprioception in stroke patients with hemiplegic shoulder pain. Fourteen patients aged 18-80 years with hemiplegic shoulder pain will be randomized into two groups.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18 and 80 years
- Presence of shoulder pain on the hemiplegic side with a Numeric Rating Scale (NRS) score \> 3
- At least 1 month since the cerebrovascular event (subacute and chronic stroke patients)
- Active shoulder flexion range of motion \> 90 degrees (required for the application of the laser pointer-assisted joint position sense test)
- First-ever, unilateral hemiplegia
You likely can't join if
- Mini-Mental State Examination score \< 24 indicating cognitive impairment
- Presence of aphasia
- Shoulder spasticity with a Modified Ashworth Scale score \> 2
- Brunnstrom upper extremity motor stage \< 3
- Botulinum toxin type A injection within the last 3 months to muscles affecting shoulder joint movement (trapezius, levator scapulae, pectoralis...
- Pre-existing shoulder pathology causing pain in the hemiplegic shoulder
See the full eligibility criteria
- Age between 18 and 80 years
- Presence of shoulder pain on the hemiplegic side with a Numeric Rating Scale (NRS) score \> 3
- At least 1 month since the cerebrovascular event (subacute and chronic stroke patients)
- Active shoulder flexion range of motion \> 90 degrees (required for the application of the laser pointer-assisted joint position sense test)
- First-ever, unilateral hemiplegia
- Mini-Mental State Examination score \< 24 indicating cognitive impairment
- Presence of aphasia
- Shoulder spasticity with a Modified Ashworth Scale score \> 2
- Brunnstrom upper extremity motor stage \< 3
- Botulinum toxin type A injection within the last 3 months to muscles affecting shoulder joint movement (trapezius, levator scapulae, pectoralis major, deltoid, serratus anterior, latissimus dorsi, rhomboids, teres...
- Pre-existing shoulder pathology causing pain in the hemiplegic shoulder
- Presence of neglect syndrome
- Complex regional pain syndrome, central pain, traumatic brachial plexus injury
- Change in pain medication during the study period
- Hypersensitivity to the medication used for suprascapular nerve block (lidocaine)
- Adhesive capsulitis (frozen shoulder)
- Other shoulder pathologies such as fractures or joint replacement
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, Istanbul, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, Istanbul, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.